We are live on ! Find out more
HOWL icon

Werewolf Therapeutics
HOWL

36 hedge funds and large institutions have $73.3M invested in Werewolf Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

17% more capital invested

Capital invested by funds: $62.5M → $73.3M (+$10.8M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.48% less ownership

Funds ownership: 68% → 67.52% (-0.48%)

3% less funds holding

Funds holding: 37 → 36 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

91% less call options, than puts

Call options by funds: $1K | Put options by funds: $11K

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
10
Reduced
3
Closed
3
Calls
$1K
Puts
$11K
Net Calls
-$10K
Net Calls Change
-$11K

Top Buyers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
+$713K
2
PHS
PFM Health Sciences
California
+$244K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$99.9K
4
BlackRock
BlackRock
New York
+$98.5K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$31.8K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$670K
2
Marshall Wace
Marshall Wace
United Kingdom
-$314K
3
B
Bailard
California
-$47.1K
4
Two Sigma Investments
Two Sigma Investments
New York
-$26.2K
5
Bank of America
Bank of America
North Carolina
-$4.53K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$18.7M – – –
MAM
2
MPM Asset Management
Massachusetts
$13.1M – – –
MB
3
MPM BioImpact
Massachusetts
$7.28M – – –
PHS
4
PFM Health Sciences
California
$7.03M +$244K +86,671 +4%
RCMNY
5
Rubric Capital Management (New York)
New York
$5.9M – – –
Bank of America
6
Bank of America
North Carolina
$4.67M -$4.53K -1,608 -0.1%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$3.05M – – –
Millennium Management
8
Millennium Management
New York
$2.62M -$670K -238,101 -22%
SFM
9
Sphera Funds Management
Israel
$1.91M – – –
DF
10
DC Funds
Virginia
$1.8M – – –
LCM
11
Laurion Capital Management
New York
$1.59M – – –
Vanguard Group
12
Vanguard Group
Pennsylvania
$1.41M – – –
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$1.21M – – –
SSA
14
Schonfeld Strategic Advisors
New York
$996K +$713K +253,284 +345%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$504K +$99.9K +35,483 +27%
BCM
16
Bridgeway Capital Management
Texas
$261K +$10.7K +3,800 +5%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$238K – – –
BlackRock
18
BlackRock
New York
$226K +$98.5K +34,987 +90%
State Street
19
State Street
Massachusetts
$155K – – –
Edgewood Management
20
Edgewood Management
Connecticut
$153K – – –
Renaissance Technologies
21
Renaissance Technologies
New York
$131K +$24.8K +8,800 +26%
HSA
22
HBK Sorce Advisory
Pennsylvania
$80.7K – – –
Northern Trust
23
Northern Trust
Illinois
$79.5K +$17.3K +6,161 +31%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$75.1K +$31.8K +11,287 +85%
Prudential Financial
25
Prudential Financial
New Jersey
$60.4K – – –
1
2

HOWL Hedge Fund Activity: Q2 2023 in Review

36 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2023, worth a combined $73.3M — up 17% from $62.5M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of HOWL and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 10 added.

The largest buyer was Schonfeld Strategic Advisors, adding an estimated $713K. The largest seller was Millennium Management, cutting an estimated $670K.

  • 36 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2023, down from 37 in Q1 2023.
  • Funds reported $73.3M of Werewolf Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 2 funds opened new Werewolf Therapeutics positions in Q2 2023 and 3 closed out, a net change of -1 holder.
  • The largest Werewolf Therapeutics buyer in Q2 2023 was Schonfeld Strategic Advisors, an estimated $713K added.
  • The largest Werewolf Therapeutics seller in Q2 2023 was Millennium Management, an estimated $670K sold.

Based on aggregated 13F filings for Q2 2023.